Moderate/severe erectile dysfunction in patients with antiphospholipid syndrome


Autoria(s): Lopes Gallinaro, A.; Silva, C. A.; Rabelo Junior, C. N.; Correia Caleiro, M. T.; de Carvalho, J. F.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

05/11/2013

05/11/2013

2012

Resumo

Purpose: To evaluate sexual function of antiphospholipid syndrome (APS) patients using the Brazilian version of the validated International Index of Erectile Function (IIEF). Materials and methods: Eleven APS male patients (Sapporo criteria) were age and race-matched with 22 healthy controls. Demographic and clinical data, drug use and antiphospholipid antibodies were evaluated. The IIEF was also self-applied. Results: Mean age (p = 0.114), frequency of Caucasian race (p = 1.00) and married status (p = 0.438) were similar in APS and controls. Mean disease duration was 8.8 +/- 4.6 years. Erectile dysfunction (ED) was frequently observed in APS versus controls (45.5 vs. 4.5%, p = 0.0096), especially moderate/severe ED (p = 0.0081). The total IIEF score (49.6 vs. 67.1, p = 0.019), erectile function (19.6 vs. 28.1, p = 0.005) and intercourse satisfaction (7.8 vs. 11.9, p = 0.009) were lower in patients than in controls. No differences were seen in orgasmic function (p = 0.114), sexual desire (p = 0.123) or overall satisfaction (p = 0.097) between the groups. The comparison between APS patients with ED (n = 5) and without ED (n = 6) revealed more arterial events in APS with ED (100 vs. 16.7%, p = 0.0152), and also longer disease duration (12 [7-16] vs. 5.5 [2-13] years, p = 0.031). A trend towards lower venous events (20 vs. 83.3%, p = 0.0801) and higher renal thrombotic microangiopathy (60% vs. 0, p = 0.0606) was observed in APS patients with ED. Demographics, clinical manifestations, smoking and antiphospholipid antibodies positivity were similar in both groups. Conclusion: To our knowledge, this was the first study that demonstrated moderate/severe ED in almost 50% of cases of a rare autoimmune disease. This alteration was linked to arterial events and longer disease duration. Lupus (2012) 21, 319-323.

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPQ [300248/2008-3, 300665/2009-1]

Federico Foundation

Federico Foundation

Identificador

LUPUS, LONDON, v. 21, n. 3, supl. 1, Part 1, pp. 319-323, MAR, 2012

0961-2033

http://www.producao.usp.br/handle/BDPI/41036

10.1177/0961203311427552

http://dx.doi.org/10.1177/0961203311427552

Idioma(s)

eng

Publicador

SAGE PUBLICATIONS LTD

LONDON

Relação

LUPUS

Direitos

closedAccess

Copyright SAGE PUBLICATIONS LTD

Palavras-Chave #ANTIPHOSPHOLIPID SYNDROME #ERECTILE DYSFUNCTION #IMPOTENCE #INTERNATIONAL INDEX OF ERECTILE FUNCTION (IIEF) BRAZILIAN VERSION #ANKYLOSING-SPONDYLITIS #MEN #ONSET #RISK #RHEUMATOLOGY
Tipo

article

original article

publishedVersion